This Article Abstract Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aqeilan, R. I. Articles by Elenius, K. Search for Related Content PubMed PubMed Citation Articles by Aqeilan, R. I. Articles by Elenius, K.

Association of Wwox with ErbB4 in Breast Cancer

¹ Department of Molecular Virology, Immunology and Medical Genetics, Human Cancer Genetics Program, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio; ² MediCity Research Laboratory, and Department of Medical Biochemistry and Molecular Biology, University of Turku; ³ Turku Postgraduate School of Biomedical Sciences; ⁴ Department of Oncology, Turku University Central Hospital, Turku, Finland; ⁵ Department of Oncology, University of Helsinki, Helsinki, Finland; ⁶ Laboratory of Cancer Biology, Institute of Medical Technology, Tampere University, and Tampere University Hospital, Tampere, Finland; and ⁷ Weis Center for Research, Geisinger Clinic, Danville, Pennsylvania

Requests for reprints: Rami I. Aqeilan, Human Cancer Genetics, Ohio State University, Biomedical Research Tower, Room 1088, 460 West 12th Avenue, Columbus, OH 43210. Phone: 614-292-5906; Fax: 614-292-4097; E-mail: rami.aqeilan{at}osumc.edu or Klaus Elenius, Department of Medical Biochemistry and Molecular Biology, University of Turku, Kiinamyllynkatu 10, FIN-20520 Turku, Finland. Phone: 358-2-3337569; Fax: 358-2-3337229; E-mail: klaus.elenius{at}utu.fi.

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
WWOX, WW domain-containing oxidoreductase, is a tumor suppressor that is altered in many human cancers, including breast cancer. Wwox interacts with the ErbB4 receptor, reduces nuclear translocation of the cleaved intracellular domain of ErbB4, and inhibits its transactivation function mediated through Yes-associated protein. Here, we assessed the clinical significance of the Wwox-ErbB4 association. We determined Wwox protein expression by immunohistochemistry in a series of 556 breast cancers. Wwox expression was absent in 36% of the cancers, and loss of Wwox expression was associated with unfavorable outcome (P = 0.02). Membranous location of ErbB4 was associated with favorable survival compared with women whose cancer lacked such ErbB4 expression (P = 0.02). Wwox expression was strongly associated with membranous ErbB4 localization (P = 0.0003) and with overall ErbB4 expression (P = 0.0002). Coexpression of membranous ErbB4 and Wwox was associated with favorable outcome compared with cases with membranous ErbB4 and no Wwox immunoreactivity (P = 0.002). In vitro, Wwox associated with the two ErbB4 isoforms, JM-a CYT-1 and JM-a CYT-2, expressed in breast cancer. Moreover, expression of Wwox both in vitro and in vivo led to accumulation of total full-length membrane-associated ErbB4. These results suggest that expression of Wwox is associated with ErbB4 expression and that their coexpression has prognostic significance in breast cancer. [Cancer Res 2007;67(19):9330–6]

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
The WWOX gene encodes a protein with tumor suppressor function, a WW domain-containing oxidoreductase. WWOX spans the second most common chromosomal fragile site 16D (FRA16D) and is frequently inactivated very early in breast cancer (1). Loss of heterozygosity, homozygous deletion, and chromosomal translocation affecting WWOX have been reported in several types of cancer, including breast, ovarian, esophageal, and stomach carcinoma and multiple myeloma (2, 3). We and others have shown that ectopic expression of WWOX in cancer cells lacking endogenous Wwox results in significant growth inhibition and prevents the development of tumors in athymic nude mice (4). In addition, we have reported that restoration of Wwox expression results in caspase-3–mediated apoptosis (4). Recently, we have shown that targeted deletion of the Wwox gene in the mouse results in increased tumor incidence and multiplicity, indicating that WWOX is a bona fide tumor suppressor (5).

We have previously shown that Wwox interacts with ErbB4 receptor kinase (CYT-2 isoform) via its first WW domain (6). ErbB4 is expressed as four alternatively spliced isoforms. Alternative splicing occurs within the intracellular cytoplasmic domain (isoforms CYT-1 and CYT-2; ref. 7) and within the extracellular juxtamembrane region (isoforms JM-a and JM-b; ref. 8), which generates receptors with different signaling capabilities (9, 10). The only JM isoform expressed in breast cancer is JM-a, whereas both CYT isoforms are present (11). JM-a isoforms can be cleaved by the tumor necrosis factor-–converting enzyme, which triggers a secondary cleavage event by -secretase that releases a soluble intracellular domain (ICD) fragment. The ICD can translocate into the nucleus and regulate gene transcription (10, 12–15). Wwox binds ErbB4 at the cell membrane and in the cytoplasm and hence prevents ICD translocation into the nucleus (6). We have also previously reported that both WW domain-containing proteins, Wwox and Yes-associated protein (YAP), compete for interaction with ErbB4, thus determining its transcriptional transactivation activity. Whereas YAP coactivates ErbB4 transactivation, Wwox suppresses this function (6).

Recently, we reported that high ErbB4 protein expression level at the cell membrane associates with a favorable outcome in estrogen receptor (ER)-positive breast cancer cases (11). By contrast, nuclear ErbB4 associates with poor survival compared with women whose cancer has membranous ErbB4 localization. Furthermore, overexpression of cleavable ErbB4 isoform enhances nuclear ErbB4 accumulation, proliferation, anchorage-independent growth, and estrogen response element–mediated transcriptional activity, thus suggesting a tumor-promoting role for ErbB4 ICD in the nucleus (11).

In this study, we set to determine the relevance of Wwox-ErbB4 interaction and its association with breast cancer survival. To this end, we investigated the expression of Wwox and its association with ErbB4 expression and subcellular localization in clinical breast cancer samples. Our findings suggest that expression of Wwox associates with overall expression of ErbB4 and membranous ErbB4 localization and that Wwox-ErbB4 association results in favorable patient survival. Moreover, results from in vitro experiments indicate that Wwox interacts with ErbB4 isoforms present in breast cancer tissues and that this association up-regulates membrane-associated full-length ErbB4. These findings suggest that Wwox-ErbB4 association has a significant implication on the clinical outcome of breast cancer patients.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Patients. Tissue microarrays, including representative 0.6-mm-diameter breast tumor samples from 556 patients, with a median of 10 years of clinical follow-up after the diagnosis of breast cancer, were analyzed. The preparation of the microarrays and histopathology of the tumors have been described elsewhere (16).

Immunohistochemistry. Immunohistochemical analysis of the breast cancer tissue array for ErbB4 expression has been described (11). Wwox expression was detected using a polyclonal rabbit anti-Wwox (17) diluted at 1:4,000. Unstained 5-µm sections, mounted on glass slides, were deparaffinized through serial baths in xylene and rehydrated in a graded series of alcohol and water. To remove any endogenous peroxidase activity, the sections were soaked in absolute methanol containing 1% hydrogen peroxide for 15 min at room temperature. After being washed with PBS for 5 min, the slides were blocked with normal goat serum diluted 1:40 in PBS (pH 7.2) containing 1% bovine serum albumin for 20 min to inhibit nonspecific background staining. Antigen retrieval was done by heating sections in 0.01 mol/L sodium citrate buffer (pH 6.0) using a microwave oven (620 W) for three 5-min periods. Subsequently, sections were incubated with anti-Wwox primary antibody for 60 min at room temperature in a humidified box and detection was done with streptavidin-biotin complex using the LSAB2 System (DakoCytomation). Finally, sections were incubated with PBS containing 6 mg 3,3'-diaminobenzidine tetrahydrochloride (Sigma) and 100 µL 1% hydrogen peroxide per 10 mL and then lightly counterstained with Mayer's hematoxylin for 30 s, washed in running water, dehydrated, and mounted with Canadian balsam. A section of normal human breast, previously proven to be Wwox positive, was used as a positive control, whereas an invasive ductal carcinoma case that was negative for Wwox was included as a negative control.

To evaluate Wwox expression, the staining was scored by extent of stained cancer tissue area. Extent of staining was evaluated as the percentage of cells with cytoplasmic immunoreactivity in the evaluated compartment and was scored in three classes as follows: 0% to 25%, 25% to 50%, and >50%.

Statistical analyses. The ² test was used to test for associations between factors. Life tables were calculated according to the Kaplan-Meier method. Distant disease-free survival was calculated from the date of the diagnosis to the occurrence of metastases outside the locoregional area or death from breast cancer, whichever came first. Survival curves were compared with the log-rank test and hazard ratios (HR) were calculated using Cox regression. All P values are two tailed.

Cell culture and transfection. COS-7 fibroblasts and MCF-7 breast cancer cells were maintained in DMEM supplemented with 10% FCS (Bioclear) and 1% L-glutamine-penicillin-streptomycin solution (Sigma). Cells were transiently transfected with FuGENE 6 (Roche Diagnostics) according to the manufacturer's recommendations. The amount of total DNA used for transfection was equalized in each experiment by addition of empty expression vectors. Mouse embryonic fibroblasts (MEF) were derived from 13.5-day-old embryos from Wwox heterozygous intercross (5) as described previously (18). Briefly, after removal of the head and internal organs, embryos were rinsed with PBS, minced, and resuspended in DMEM containing 10% fetal bovine serum and 2 mmol/L glutamine, 0.1 mmol/L MEM nonessential amino acids, and 100 IU/mL penicillin and 100 µg/mL streptomycin (Sigma).

Coimmunoprecipitation analyses. To study the interaction between Wwox and ErbB4 isoforms, COS-7 cells were transiently transfected with pcDNA3.1ErbB4JM-aCYT-1, pcDNA3.1ErbB4JM-aCYT-2 (10), pCMV-MYC-WWOX, or pCMV-MYC-WWOX-Y33R (6) in different combinations as indicated in figures. Cells were starved without serum for 6 h, stimulated with 0 or 100 ng/mL phorbol 12-myristate 13-acetate (PMA) for 30 min to stimulate ErbB4 cleavage, and lysed as described previously (9). Aliquots of the lysates corresponding to 650 µg of total protein were immunoprecipitated with anti-ErbB4 antibody (HFR-1; NeoMarkers) or with an anti-Myc antibody (Zymed) and subsequently analyzed by Western blotting using an anti-Myc or anti-ErbB4 antibody (Santa Cruz Biotechnology), respectively.

ErbB4 degradation. To study the effect of Wwox on the stability of ErbB4, COS-7 cells were transfected with pcDNA3.1ErbB4JM-aCYT-1 with or without pCMV-MYC-WWOX. Cells were starved without serum for 2 h followed by addition of protein synthesis inhibitor cycloheximide (100 µg/mL) for 2, 4, or 6 h. After lysis, 30 µg samples of total protein were analyzed by Western blotting using an anti-ErbB4 antibody. Expression of Myc-tagged Wwox protein was detected with an anti-Myc antibody.

RNA interference. A pool of small interfering RNA (siRNA) duplexes directed against WWOX or GFP was designed and constructed by Dharmacon. MCF-7 cells were transfected with 50 or 100 nmol/L of siRNA using LipofectAMINE reagent (Invitrogen). Forty-eight hours after siRNA transfection, cells were collected and analyzed by immunoblotting using monoclonal anti-Wwox (19), polyclonal anti-ErbB4, and monoclonal anti-glyceraldehyde-3-phosphate dehydrogenase (Gapdh; Calbiochem) antibodies.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Loss of Wwox expression associates with nodal metastases. To assess the clinical significance of Wwox protein expression in breast cancer, a tissue array including 556 breast cancer samples was analyzed by immunohistochemistry and compared with samples of normal mammary gland tissue. The Wwox immunoreactivity in cancer tissue sample was scored as normal if >50% of the cells were Wwox positive, reduced if 25% to 50% of cells were positive, or absent if Wwox expression was present in 0% to 25% of cells. Representative examples of breast cancer sections stained with anti-Wwox antibody are shown in Supplementary Fig. S1. Normal Wwox expression was detected in 50% of patients, reduced expression in 14% of the patients, whereas 36% of patients were negative for Wwox immunoreactivity.

Associations of Wwox immunoreactivity with clinical and histopathologic characteristics are listed in Supplementary Table S1. Loss of Wwox expression significantly associated with the number of metastatic axillary lymph nodes (P = 0.02). However, molecular markers reflecting cancer cell survival or proliferation (i.e., loss of p53 staining or high Ki-67 expression) did not associate with Wwox expression (P = 0.94 or 0.67, respectively).

Loss of Wwox expression associates with poor survival. In Kaplan-Meier survival analysis, absent Wwox expression (Wwox present in 0–25% of cells) significantly associated with poor distant disease-free survival when compared with normal or reduced Wwox expression [Wwox in >25% of cells; HR, 1.51; 95% confidence interval (95% CI), 1.06–2.16; P = 0.021; Fig. 1A ]. Because Wwox expression has previously been shown to correlate with ER negativity in breast cancer (20), the analysis was repeated after stratifying the patients according to their ER status. In women with ER-negative cancer, loss of Wwox expression was significantly associated with shorter survival (HR, 1.78; 95% CI, 1.01–3.15; P = 0.045; Fig. 1C). However, association between Wwox expression and survival did not reach significance in the subgroup of ER-positive patients (HR, 1.32; 95% CI, 0.79–2.22; P = 0.29; Fig. 1B). A similar tendency for an association of lost Wwox expression with unfavorable survival was observed in the subgroup of progesterone receptor (PgR)-negative (HR, 1.67; 95% CI, 0.99–2.80; P = 0.05) but not in PgR-positive (HR, 1.26; 95% CI, 0.70–2.25; P = 0.43) patients (Supplementary Fig. S2A and B). Because absent Wwox expression tended to associate with cases without ErbB2 amplification (Supplementary Table S1), the prognostic significance of Wwox expression was further analyzed in subgroups negative or positive for ErbB2 amplification. Again, loss of Wwox expression was associated with unfavorable survival of ErbB2-negative (HR, 1.65; 95% CI, 1.08–2.54; P = 0.02) but not of ErbB2-positive (HR, 1.55; 95% CI, 0.71–3.36; P = 0.27) patients (Supplementary Fig. S2C and D). These results indicate that loss of Wwox expression is associated with unfavorable outcome, particularly in hormone receptor–negative and ErbB2-negative early breast cancer.

View larger version (10K): [in this window] [in a new window] [Download PPT slide]   Figure 1. Association of Wwox protein expression with survival of breast cancer patients. Kaplan-Meier survival (distant disease-free survival) curves comparing Wwox expression status analyzed by immunohistochemistry are shown. The analysis included all patients (A), ER-positive patients (B), or ER-negative patients (C).

View larger version (12K): [in this window] [in a new window] [Download PPT slide]   Figure 2. Association of Wwox protein expression analyzed simultaneously with ErbB4 protein localization with survival of breast cancer patients. Kaplan-Meier survival (distant disease-free survival) curves comparing immunohistochemical Wwox expression status and subcellular localization of ErbB4 immunoreactivity are shown.

Presence of Wwox is associated with ErbB4 localization at the cell membrane but not with ErbB4 nuclear expression. The majority of breast cancers that expressed Wwox (186 of 283, 66%) were also positive for ErbB4 staining (in any subcellular compartment), whereas only 29% (17 of 58) of ErbB4-negative patients showed Wwox immunoreactivity (P = 0.0002; Table 1 ). Because Wwox expression has been suggested to prevent nuclear accumulation of ErbB4 in vitro (6), we investigated whether Wwox expression is associated with ErbB4 subcellular localization in vivo. In particular, we set to examine whether normal expression of Wwox is associated with retained membranous ErbB4 localization and whether loss of Wwox expression is linked with nuclear ErbB4 localization. Immunohistochemical analyses indicated that Wwox expression was positively associated with ErbB4 localization at the cell membrane (P = 0.0003; Table 1). In contrast, no significant association was observed between Wwox expression and nuclear ErbB4 immunoreactivity (P = 0.82). These data show that expression of Wwox is associated with localization of ErbB4 at the cell membrane in breast cancer.

View larger version (28K): [in this window] [in a new window] [Download PPT slide]   Figure 3. Wwox interacts with ErbB4 isoforms present in breast cancer tissues. COS-7 cells were transfected with plasmids encoding ErbB4 isoforms JM-a CYT-1 or JM-a CYT-2 and either empty vector, wt Myc-Wwox, or Myc-Wwox-Y33R with mutated NH2-terminal WW1 domain. To stimulate ErbB4 cleavage, cells were treated for 30 min with or without 100 ng/mL PMA. Cell lysates were precipitated with anti-ErbB4 antibody (A) or with an anti-Myc antibody (B) and subsequently analyzed by reciprocal Western blotting using an anti-Myc (A) or anti-ErbB4 antibody (B). Original loading of ErbB4 and Wwox proteins was also controlled by Western blot analyses as indicated.

View larger version (39K): [in this window] [in a new window] [Download PPT slide]   Figure 4. Wwox expression stimulates accumulation of full-length ErbB4. A, COS-7 cells transiently expressing ErbB4 JM-a CYT-1 alone (lanes 1–4) or together with Wwox (lanes 5–8) were starved without serum for 2 h followed by addition of protein synthesis inhibitor cycloheximide (CHX; 100 µg/mL) for 2, 4, or 6 h. Cell lysates were analyzed by Western blotting using an anti-ErbB4 antibody. Expression of Myc-Wwox was controlled with an anti-Myc antibody. B, effect of RNA interference directed against endogenous Wwox on endogenous ErbB4 protein level. MCF-7 cells were transfected with 100 nmol/L siRNAs as indicated. Forty-eight hours after treatment with siRNA, cells were harvested and whole-cell extracts were resolved by Western blot analysis with anti-ErbB4, anti-Wwox, and anti-Gapdh antibodies. C, MEFs were isolated from 13.5 d Wwox-null embryos and their corresponding wt control embryos. Whole-cell extracts from the different clones were resolved by SDS-PAGE, and Western blot analysis was done using anti-ErbB4, anti-Wwox, and anti-Gapdh antibodies.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

Consistent with previous studies (17, 20), we observed that a significant proportion of breast cancer samples exhibited either reduced (14%) or total loss (36%) of Wwox expression. Absence of Wwox expression was associated with the number of positive axillary nodes as well as with poor survival in the unselected series of 556 patients. Interestingly, the association of Wwox loss with unfavorable outcome was preserved in the subgroup of ER-negative but not in ER-positive patients. Similarly, Wwox loss was associated with poor survival in PgR-negative but not in PgR-positive patients. Finally, an association was found between Wwox loss and poor survival in the subset of ErbB2-negative breast cancer but not in ErbB2-positive disease. These observations imply that loss of Wwox signaling may be biologically significant in the triple-negative (ER^–, PgR^–, and ErbB2^–) high-risk breast cancer (22). Indeed, loss of Wwox expression was significantly associated with unfavorable survival in the triple-negative subset of cases (P = 0.04) but not in non–triple-negative cancers (P = 0.34; data not shown).

In a previous study, we showed that Wwox, via its first WW domain, associates with the PPxY motif of ErbB4 and functions as a regulator of ErbB4 ICD subcellular localization (6). Wwox inhibits nuclear translocation of ICD and hence suppresses its transactivating ability. Here, we extend these findings by showing that Wwox equally binds both of the ErbB4 isoforms present in breast cancer tissue in vivo (i.e., ErbB4 JM-a CYT-1 and JM-a CYT-2) and that expression of Wwox correlates positively with expression of ErbB4 and localization of ErbB4 at the cell membrane. In addition, we found a significant association between coexpression of Wwox and ErbB4 at the cell membrane and favorable survival compared with patients whose cancer expressed ErbB4 at the membrane but lacked Wwox or patients with detectable Wwox but no ErbB4 signal at the membrane. Importantly, survival of the 17% of patients with ErbB4 immunoreactivity at the membrane is favorable regardless of the Wwox status (5-year survival rate of 91% as opposed to 79% in the whole population of 2,459 patients included in the tissue microarrays used; refs. 11, 16), whereas combining the Wwox status to the prognostic evaluation improves the prognosis even further. Indeed, the 5-year survival rate is 94% for those 16% of patients with normal or reduced Wwox (>25% positive cells) and ErbB4 at the membrane and 98% for those 12% with normal Wwox (>50% positive cells) and ErbB4 at the membrane.

The WWOX gene spans a fragile genomic region that is frequently altered in preneoplastic and invasive breast carcinoma (1–3, 17, 20). Recent observations by the Huebner laboratory suggest that Wwox expression can also be down-regulated by DNA hypermethylation of the promoter region of WWOX (23). Importantly, our results from Wwox knockout mice indicate that Wwox heterozygous mice exhibit a higher incidence of spontaneous tumors compared with the wt control mice (5). The molecular mechanism underlying the tumor suppressor function of Wwox, however, still remains to be fully elucidated. Our present study suggests that Wwox association with ErbB4 may contribute to Wwox tumor suppressor function in breast cancer cells. We have also previously shown that Wwox binds AP2 transcription factors ( and ) in the cytoplasm and suppresses their transactivation potential (24), suggesting that, in addition to ErbB4, Wwox loss in breast cancer can affect other signal transduction pathways contributing to tumorigenicity.

Our data indicate that the mechanism by which Wwox regulates ErbB4 function involves more than one mechanism. In addition to suppressing the nuclear activity of ErbB4 (6), interaction between Wwox and ErbB4 may simultaneously lead to enhanced stability of membrane-associated full-length ErbB4. One possible mechanism could be by inhibition of protein degradation through lysosomal or proteasomal pathways. For example, membrane-coupled HECT-type of ubiquitin ligases that also include WW domains for protein-protein interactions could compete with Wwox for an interaction with full-length ErbB4 within the membrane environment (25, 26).

Whereas Wwox is a relatively well-defined tumor suppressor (2, 5), the role of ErbB4 in breast cancer is complicated by the existence of functionally different ErbB4 isoforms and the extent to which some of these isoforms are processed into intracellular signaling fragments (21, 27, 28). Most clinical studies have shown a significant association between total ErbB4 expression and favorable prognostic indicators, particularly ER positivity (11, 29, 30), but reports on association with survival have been contradictory (28, 31). Our recent observations, however, indicate that ErbB4 has differential prognostic significance when functioning in different subcellular localizations: whereas full-length ErbB4 at the cell membrane associates with favorable survival, localization of ErbB4 ICD in the nucleus associates with worse prognosis (11). Similar findings about the association of nuclear ErbB4 with unfavorable survival have recently been reported by Tovey et al. (32). We found in our prior study that in vitro overexpression of a cleavable ErbB4 isoform in breast cancer cells results in enhanced proliferation, anchorage-independent growth, and estrogen response element–mediated transcriptional activity (11). ErbB4 ICD is a direct coregulator of ER in the nucleus and is required for estrogen-stimulated proliferation of the T-47D breast cancer cell line (33). Therefore, neutralizing nuclear ErbB4 and stabilizing intact membrane-anchored ErbB4 could both be independent mechanisms to suppress breast cancer cell growth.

In conclusion, we propose a model (Fig. 5 ) in which normally expressed Wwox binds the COOH-terminal fragment of ErbB4, which may both prevent translocation of ErbB4 ICD into the nucleus and stabilize the full-length ErbB4 at the cell membrane. This favors signaling via the full-length ErbB4 as opposed to the nuclear ErbB4 and is associated with favorable survival in early breast cancer. When Wwox is absent or its function is lost, this balance is disturbed promoting tumor progression. Simultaneous expression of Wwox and ErbB4 localization on the cell membrane may be a novel means to define a subgroup of breast cancer patients with a favorable outcome.

View larger version (3K): [in this window] [in a new window] [Download PPT slide]   Figure 5. A schematic model of Wwox-ErbB4 association in breast cancer. A, when Wwox is expressed normally, it physically associates with ErbB4 stabilizing full-length ErbB4 at the cell membrane. In addition, it may bind ErbB4 ICD and other PPxY motif-containing proteins, such as AP2 transcription factors, in the cytosol, preventing their transcriptional transactivation activity in the nucleus. B, when Wwox is lost, full-length ErbB4 is down-regulated at the cell membrane and PPxY motif-containing proteins, including ErbB4 ICD and AP2 transcription factors, are free to translocate into the nucleus.

	Acknowledgments

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Maria Tuominen for excellent technical assistance and Muller Fabbri for fruitful discussion.

	Footnotes

 
Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Received 6/11/07. Accepted 7/18/07.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 2000;60:2140–5.[Abstract/Free Full Text]
2. Aqeilan RI, Croce CM. WWOX in biological control and tumorigenesis. J Cell Physiol 2007;212:307–10.[CrossRef][Medline]
3. Paige AJ, Taylor KJ, Taylor C, et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A 2001;98:11417–22.[Abstract/Free Full Text]
4. Fabbri M, Iliopoulos D, Trapasso F, et al. WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci U S A 2005;102:15611–6.[Abstract/Free Full Text]
5. Aqeilan RI, Trapasso F, Hussain S, et al. Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci U S A 2007;104:3949–54.[Abstract/Free Full Text]
6. Aqeilan RI, Donati V, Palamarchuk A, et al. WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res 2005;65:6764–72.[Abstract/Free Full Text]
7. Elenius K, Choi CJ, Paul S, Santiestevan E, Nishi E, Klagsbrun M. Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 1999;18:2607–15.[CrossRef][Medline]
8. Elenius K, Corfas G, Paul S, et al. A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester. J Biol Chem 1997;272:26761–8.[Abstract/Free Full Text]
9. Kainulainen V, Sundvall M, Maatta JA, Santiestevan E, Klagsbrun M, Elenius K. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem 2000;275:8641–9.[Abstract/Free Full Text]
10. Määttä JA, Sundvall M, Junttila TT, et al. Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell 2006;17:67–79.[Abstract/Free Full Text]
11. Junttila TT, Sundvall M, Lundin M, et al. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 2005;65:1384–93.[Abstract/Free Full Text]
12. Komuro A, Nagai M, Navin NE, Sudol M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 2003;278:33334–41.[Abstract/Free Full Text]
13. Ni CY, Murphy MP, Golde TE, Carpenter G. -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001;294:2179–81.[Abstract/Free Full Text]
14. Sardi SP, Murtie J, Koirala S, Patten BA, Corfas G. Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain. Cell 2006;127:185–97.[CrossRef][Medline]
15. Williams CC, Allison JG, Vidal GA, et al. The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J Cell Biol 2004;167:469–78.[Abstract/Free Full Text]
16. Joensuu H, Isola J, Lundin M, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003;9:923–30.[Abstract/Free Full Text]
17. Guler G, Uner A, Guler N, et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 2004;100:1605–14.[CrossRef][Medline]
18. McCurrach ME, Lowe SW. Methods for studying pro- and antiapoptotic genes in nonimmortal cells. Methods Cell Biol 2001;66:197–227.[Medline]
19. Aqeilan RI, Pekarsky Y, Herrero JJ, et al. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci U S A 2004;101:4401–6.[Abstract/Free Full Text]
20. Nunez MI, Ludes-Meyers J, Abba MC, et al. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat 2005;89:99–105.[CrossRef][Medline]
21. Junttila TT, Sundvall M, Maatta JA, Elenius K. ErbB4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc Med 2000;10:304–10.[CrossRef][Medline]
22. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007;8:235–44.[CrossRef][Medline]
23. Iliopoulos D, Guler G, Han SY, et al. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 2005;24:1625–33.[CrossRef][Medline]
24. Aqeilan RI, Palamarchuk A, Weigel RJ, Herrero JJ, Pekarsky Y, Croce CM. Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2 transcription factor. Cancer Res 2004;64:8256–61.[Abstract/Free Full Text]
25. Chang NS, Hsu LJ, Lin YS, Lai FJ, Sheu HM. WW domain-containing oxidoreductase: a candidate tumor suppressor. Trends Mol Med 2007;13:12–22.[CrossRef][Medline]
26. Melino G, Knight RA, Cesareni G. Degradation of p63 by Itch. Cell Cycle 2006;5:1735–9.[Medline]
27. Carpenter G. ErbB-4: mechanism of action and biology. Exp Cell Res 2003;284:66–77.[CrossRef][Medline]
28. Gullick WJ. c-erbB-4/HER4: friend or foe? J Pathol 2003;200:279–81.[CrossRef][Medline]
29. Bacus SS, Chin D, Yarden Y, Zelnick CR, Stern DF. Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am J Pathol 1996;148:549–58.[Abstract]
30. Knowlden JM, Gee JM, Seery LT, et al. c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 1998;17:1949–57.[CrossRef][Medline]
31. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004;91:1532–42.[CrossRef][Medline]
32. Tovey SM, Dunne B, Witton CJ, Cooke TG, Bartlett JM. HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4. Breast Cancer Res 2006;8:R19.[CrossRef][Medline]
33. Zhu Y, Sullivan LL, Nair SS, et al. Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res 2006;66:7991–8.[Abstract/Free Full Text]

This article has been cited by other articles:

				R. S. Muraoka-Cook, M. A. Sandahl, K. E. Strunk, L. C. Miraglia, C. Husted, D. M. Hunter, K. Elenius, L. A. Chodosh, and H. S. Earp III ErbB4 Splice Variants Cyt1 and Cyt2 Differ by 16 Amino Acids and Exert Opposing Effects on the Mammary Epithelium In Vivo Mol. Cell. Biol., September 15, 2009; 29(18): 4935 - 4948. [Abstract] [Full Text] [PDF]

				L.-J. Hsu, L. Schultz, Q. Hong, K. Van Moer, J. Heath, M.-Y. Li, F.-J. Lai, S.-R. Lin, M.-H. Lee, C.-P. Lo, et al. Transforming Growth Factor {beta}1 Signaling via Interaction with Cell Surface Hyal-2 and Recruitment of WWOX/WOX1 J. Biol. Chem., June 5, 2009; 284(23): 16049 - 16059. [Abstract] [Full Text] [PDF]

				E. Matteucci, P. Bendinelli, and M. A. Desiderio Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells Carcinogenesis, June 1, 2009; 30(6): 937 - 945. [Abstract] [Full Text] [PDF]

				S.-M. Feng, R. S. Muraoka-Cook, D. Hunter, M. A. Sandahl, L. S. Caskey, K. Miyazawa, A. Atfi, and H. S. Earp III The E3 Ubiquitin Ligase WWP1 Selectively Targets HER4 and Its Proteolytically Derived Signaling Isoforms for Degradation Mol. Cell. Biol., February 1, 2009; 29(3): 892 - 906. [Abstract] [Full Text] [PDF]

				X. Li, P. C. Galipeau, C. A. Sanchez, P. L. Blount, C. C. Maley, J. Arnaudo, D. A. Peiffer, D. Pokholok, K. L. Gunderson, and B. J. Reid Single Nucleotide Polymorphism-Based Genome-Wide Chromosome Copy Change, Loss of Heterozygosity, and Aneuploidy in Barrett's Esophagus Neoplastic Progression Cancer Prevention Research, November 1, 2008; 1(6): 413 - 423. [Abstract] [Full Text] [PDF]

				C.-P. Chuu, R.-Y. Chen, J. L. Barkinge, M. F. Ciaccio, and R. B. Jones Systems-Level Analysis of ErbB4 Signaling in Breast Cancer: A Laboratory to Clinical Perspective Mol. Cancer Res., June 1, 2008; 6(6): 885 - 891. [Abstract] [Full Text] [PDF]

				M. Sundvall, A. Korhonen, I. Paatero, E. Gaudio, G. Melino, C. M. Croce, R. I. Aqeilan, and K. Elenius Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms PNAS, March 18, 2008; 105(11): 4162 - 4167. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aqeilan, R. I. Articles by Elenius, K. Search for Related Content PubMed PubMed Citation Articles by Aqeilan, R. I. Articles by Elenius, K.